Stock warrant tracker
This stock warrant tracker lists recent SEC filings in which a small-cap company issued warrants: priced offerings on Form 424B4, prospectus supplements on 424B5, and unregistered sales reported under Item 3.02 of Form 8-K. Warrants give their holders the right to buy new shares at a set price, so every new warrant series is potential future dilution.
| Company | Accepted | Source | What the filing says | Warrant series in Signal8 summary | Filing |
|---|---|---|---|---|---|
| SEV Aptera Motors Corp | Nov 10, 2026, 5:30 PM ET | Unregistered sale (8-K 3.02) | Aptera Motors entered into a securities purchase agreement on November 10, 2026 for a registered direct offering of 3,428,571 Class B shares at $1.75 per share, plus concurrent unregistered warrants for another 3,428,571 shares at a $2.05... | 7 | 8-K |
| PEPG PepGen Inc. | Nov 10, 2026, 5:06 PM ET | Prospectus supplement (424B5) | PepGen Inc. filed a preliminary prospectus supplement (424B5) on November 10, 2026 for a $125,000,000 underwritten offering of common stock and pre-funded warrants, led by Leerink Partners, Stifel and Guggenheim Securities. | 0 | 424B5 |
| JDZG JIADE Ltd | Nov 10, 2026, 12:01 PM ET | Prospectus supplement (424B5) | JIADE Ltd (JDZG) priced a US$1.2 million registered direct offering of 550,000 Class A shares at US$0.18 plus pre-funded warrants for 6,116,666 shares at US$0.179, with an investor option for up to 6,666,666 more shares. | 0 | 424B5 |
| VBIO Valion Bio, Inc. | Nov 9, 2026, 6:01 AM ET | Unregistered sale (8-K 3.02) | Valion Bio closed a $700,000 tranche under its Series B preferred purchase agreement with 3i, LP on November 6, 2026, issuing 700 Series B non-voting convertible preferred shares plus warrants for 21,539 common shares at $0.5182 per share. | 27 | 8-K |
| AUUD AUDDIA INC. | Nov 6, 2026, 5:16 PM ET | Unregistered sale (8-K 3.02) | Auddia Inc. entered into Warrant Exchange Agreements on November 6, 2026, under which holders of publicly traded warrants will exchange each warrant for two shares of common stock, exempt under Section 3(a)(9) of the Securities Act. | 7 | 8-K |
| RENX RenX Enterprises Corp. | Nov 6, 2026, 5:15 PM ET | Unregistered sale (8-K 3.02) | RenX Enterprises entered an exchange agreement on November 2, 2026 with Alto Opportunity Master Fund to swap $1,022,971.22 of outstanding convertible note debt for a new $1,037,283.93 senior convertible note plus a warrant for 644,944... | 18 | 8-K |
| BIVI BIOVIE INC. | Nov 6, 2026, 5:10 PM ET | Unregistered sale (8-K 3.02) | BioVie Inc. closed a registered direct offering and concurrent private placement on November 5, 2026, selling 960,000 Class A shares at $1.60 per share plus 2,002,500 pre-funded warrants, for aggregate gross proceeds of approximately $4.74... | 15 | 8-K |
| SILO Silo Pharma, Inc. | Nov 6, 2026, 5:08 PM ET | Unregistered sale (8-K 3.02) | Silo Pharma entered into securities purchase agreements on November 5, 2026 for a private placement of 136,005 shares at $1.50 per share plus pre-funded warrants for 430,661 shares at $1.4999, for gross proceeds of approximately $1.1... | 16 | 8-K |
| INO INOVIO PHARMACEUTICALS, INC. | Nov 6, 2026, 4:30 PM ET | Prospectus supplement (424B5) | Inovio Pharmaceuticals priced a $75 million underwritten follow-on offering at $1.05 per share, a steep ~28% discount to the prior $1.45 close, selling 58.7 million shares plus pre-funded warrants on another 12.7 million shares, with a... | 6 | 424B5 |
| NTCL NetClass Technology Inc | Nov 6, 2026, 3:09 PM ET | Prospectus supplement (424B5) | NetClass Technology (NTCL) priced a best-efforts offering of 675,000 Class A shares at $0.40 and pre-funded warrants for up to 2,325,000 shares at $0.3875, with Univest Securities acting as sole placement agent on a 7% fee. | 1 | 424B5 |
| SXTP 60 DEGREES PHARMACEUTICALS, INC. | Nov 6, 2026, 8:22 AM ET | Unregistered sale (8-K 3.02) | 60 Degrees Pharmaceuticals entered inducement letters on November 5, 2026, convincing holders to exercise 584,492 existing warrants, originally struck at $7.60 to $27.60, for cash at a reduced price of $0.90 per share. | 16 | 8-K |
| DTIL PRECISION BIOSCIENCES INC | Nov 5, 2026, 7:55 PM ET | Prospectus supplement (424B5) | Precision BioSciences priced a $125.0 million underwritten offering of 10,235,077 shares at $7.75 plus pre-funded warrants for 5,893,964 shares, with TD Cowen and Guggenheim as lead underwriters. | 3 | 424B5 |
| ANVS Annovis Bio, Inc. | Nov 5, 2026, 5:14 PM ET | Prospectus supplement (424B5) | Annovis Bio priced a $21M gross underwritten offering at $1.00 per share and accompanying warrant, selling 19M shares plus 2M pre-funded warrants and 21M five-year warrants at a $1.00 strike. | 8 | 424B5 |
| BIVI BIOVIE INC. | Nov 4, 2026, 9:56 PM ET | Prospectus supplement (424B5) | BioVie is raising roughly $4.74 million gross through a registered direct offering priced at $1.60 per share, slightly below the $1.73 November 3 close, selling 960,000 shares plus 2,002,500 pre-funded warrants via A.G.P./Alliance Global... | 15 | 424B5 |
| QNRX Quoin Pharmaceuticals Ltd. | Nov 4, 2026, 5:07 PM ET | Prospectus supplement (424B5) | Quoin Pharmaceuticals filed a 424B5 prospectus for a $150 million shelf registration covering ordinary shares represented by ADSs, warrants, subscription rights, debt securities and units, to be sold in one or more future offerings. | 10 | 424B5 |
| ANVS Annovis Bio, Inc. | Nov 4, 2026, 5:01 PM ET | Prospectus supplement (424B5) | Annovis Bio filed a preliminary prospectus supplement for an underwritten offering of common stock (or pre-funded warrants) combined with five-year warrants, priced near the last reported sale price of $1.09 per share, with Canaccord... | 8 | 424B5 |
| AIRE reAlpha Tech Corp. | Nov 4, 2026, 8:25 AM ET | Priced offering (424B4) | reAlpha Tech Corp. priced a best-efforts offering of 1,361,028 shares at $0.40 plus pre-funded warrants for 3,013,972 shares, for maximum gross proceeds of about $1.75 million and estimated net proceeds of roughly $1.35 million. | 9 | 424B4 |
| LITS Lite Strategy, Inc. | Nov 3, 2026, 4:00 PM ET | Unregistered sale (8-K 3.02) | Lite Strategy, Inc. filed an 8-K disclosing that on October 29, 2026, Green Dragon Investments LLC exercised 517,509 Advisory Warrants in a cashless exercise, receiving 517,465 shares of common stock. | 9 | 8-K |
| PRSO Peraso Inc. | Nov 3, 2026, 8:35 AM ET | Unregistered sale (8-K 3.02) | Peraso Inc. closed its $10.0 million unregistered private placement with Nant Capital on October 28, 2026, issuing 3,271,355 shares, pre-funded warrants for 16,593,563 shares, and common warrants for 19,864,918 shares at $0.5034/$0.5024... | 11 | 8-K |
| RAPP Rapport Therapeutics, Inc. | Oct 30, 2026, 5:12 PM ET | Unregistered sale (8-K 3.02) | Rapport Therapeutics closed a large triple-pronged financing on October 30, 2026, raising approximately $215.7 million net from an underwritten offering of 8,333,334 shares at $21.00 plus 1,190,476 pre-funded warrants, with the... | Not measured | 8-K |
| KLNG Koil Energy Solutions, Inc. | Oct 30, 2026, 5:12 PM ET | Unregistered sale (8-K 3.02) | Koil Energy Solutions (OTCQB: KLNG) closed a $5.6 million PIPE on October 29, 2026, selling 1,330,372 shares at $2.50 and pre-funded warrants on 919,628 shares at $2.499, with Lucid Capital Markets acting as sole placement agent for a 6.0%... | Not measured | 8-K |
| ADMT ADM TRONICS UNLIMITED, INC. | Oct 30, 2026, 2:16 PM ET | Unregistered sale (8-K 3.02) | ADM Tronics (ADMT) has entered a rolling private placement targeting $5.0 million at $0.10 per share, with $1.55 million already raised across two closings including 15.5 million shares plus warrants for another 7.75 million shares. | Not measured | 8-K |
| RAPP Rapport Therapeutics, Inc. | Oct 30, 2026, 7:04 AM ET | Prospectus supplement (424B5) | Rapport Therapeutics (NASDAQ: RAPP) priced a $200 million follow-on offering of 8,333,334 shares at $21.00 per share, a roughly 24% discount to the $27.54 close on October 27, 2026, plus pre-funded warrants on 1,190,476 shares. | Not measured | 424B5 |
| DFNS T3 Defense Inc. | Oct 29, 2026, 5:27 PM ET | Unregistered sale (8-K 3.02) | T3 Defense Inc. closed a $10 million private placement on October 22, 2026, selling 200 units at $50,000 each, with each unit containing one share of Series B Convertible Preferred Stock and warrants to purchase up to 14,851 common shares. | 7 | 8-K |
| HYFM HYDROFARM HOLDINGS GROUP, INC. | Oct 29, 2026, 5:21 PM ET | Prospectus supplement (424B5) | Hydrofarm priced a registered direct offering of 1,599,400 shares at $0.905 per share via ThinkEquity, with a concurrent private placement of 6,971,575 unregistered shares plus warrants for 9,210,975 shares at $0.78, raising roughly $1.2... | 3 | 424B5 |
| INMB Inmune Bio, Inc. | Oct 29, 2026, 7:40 AM ET | Unregistered sale (8-K 3.02) | INmune Bio entered a securities purchase agreement on October 27, 2026 with a single investor for a registered direct offering of 3,000,000 shares at $1.50 per share, with a concurrent private placement of warrants for 3,000,000 additional... | 4 | 8-K |
| MTTN Matternet, Inc. | Oct 28, 2026, 4:21 PM ET | Prospectus supplement (424B5) | Matternet, Inc. (OTCQB: MTTN) filed Prospectus Supplement No. 5 registering resale by selling stockholders of up to 51,590,925 shares of common stock, plus up to 3,535,082 shares issuable on warrant exercise, under its S-1 originally dated... | Not measured | 424B5 |
| GRDX GridAI Technologies Corp. | Oct 28, 2026, 4:16 PM ET | Unregistered sale (8-K 3.02) | GridAI Technologies Corp. entered a securities purchase agreement on October 22, 2026 to sell pre-funded warrants and common warrants covering 462,365 shares each for approximately $2.15 million in gross proceeds, in a PIPE priced at $4.65... | 18 | 8-K |
| WFF WF Holding Ltd | Oct 28, 2026, 10:05 AM ET | Prospectus supplement (424B5) | WF Holding Ltd filed Prospectus Supplement No. 2 to register up to 23,112,000 additional Ordinary Shares issuable upon zero-price exercise of 2,568,000 amended warrants held by a single investor from the October 2026 offering. | 1 | 424B5 |
| ACTU ACTUATE THERAPEUTICS, INC. | Oct 28, 2026, 8:00 AM ET | Prospectus supplement (424B5) | Actuate Therapeutics priced a public offering of 30,985,900 shares plus warrants to purchase 15,492,950 shares at $0.71 per two-share-plus-warrant unit ($0.355 per share), versus a last close of $0.40, for gross proceeds of approximately... | 6 | 424B5 |
| HYFM HYDROFARM HOLDINGS GROUP, INC. | Oct 27, 2026, 5:24 PM ET | Unregistered sale (8-K 3.02) | Hydrofarm announced a sweeping recapitalization on October 27, 2026: an $8.3 million gross registered direct offering and concurrent private placement of roughly 9.2 million shares at $0.905, plus 100% warrant coverage with 9,210,975... | 3 | 8-K |
| ACRS Aclaris Therapeutics, Inc. | Oct 27, 2026, 5:15 PM ET | Prospectus supplement (424B5) | Aclaris Therapeutics priced an underwritten offering of 7,785,714 shares of common stock plus pre-funded warrants to purchase 6,500,000 additional shares at $3.50 per share, for gross proceeds of approximately $50.0 million. | Not measured | 424B5 |
| SCQC SPACCircle Acquisition Corp. | Oct 27, 2026, 5:13 PM ET | Priced offering (424B4) | SPACCircle Acquisition Corp. priced its IPO of 10,000,000 units at $10.00 per unit, raising $100,000,000, with units expected to list on Nasdaq under symbol SCQCU. Each unit comprises one Class A share, one warrant exercisable at $11.50... | Not measured | 424B4 |
| CNXU Conexeu Sciences Inc. | Oct 27, 2026, 4:30 PM ET | Unregistered sale (8-K 3.02) | Conexeu Sciences Inc. (Nasdaq: CNXU) approved a warrant exercise inducement program on October 21, 2026, offering holders of up to 4,762,780 existing warrants (exercise price $2.30) one new Inducement Warrant for each warrant exercised... | Not measured | 8-K |
| INLF INLIF Ltd | Oct 20, 2026, 9:04 AM ET | Prospectus supplement (424B5) | INLIF Limited (Nasdaq: INLF) filed a 424B5 prospectus supplement for a best-efforts offering of up to 435,000 Class A ordinary shares plus pre-funded warrants at $1.60 per share with accompanying warrants, targeting gross proceeds of $3.75... | 3 | 424B5 |
| IRON Disc Medicine, Inc. | Oct 19, 2026, 5:42 PM ET | Prospectus supplement (424B5) | Disc Medicine filed a 424B5 prospectus supplement for a $350 million underwritten offering of common stock and pre-funded warrants, priced one day after announcing positive topline results from the pivotal Phase 3 APOLLO trial of... | Not measured | 424B5 |
| VSTM Verastem, Inc. | Oct 14, 2026, 5:18 PM ET | Prospectus supplement (424B5) | Verastem priced a $250 million underwritten offering of 30,937,500 shares at $8.00 per share, a premium to the $7.45 prior close, plus pre-funded warrants on 312,503 shares at $7.9999. | Not measured | 424B5 |
| VSTM Verastem, Inc. | Oct 14, 2026, 5:14 PM ET | Prospectus supplement (424B5) | Verastem filed a preliminary prospectus supplement (424B5) for an underwritten offering of common stock and pre-funded warrants, with joint book-runners Jefferies, Guggenheim Securities, and Cantor. | Not measured | 424B5 |
| IONQ IonQ, Inc. | Oct 14, 2026, 8:47 AM ET | Prospectus supplement (424B5) | IonQ priced a $2.0 billion offering of 20.5 million shares at $40.00 each, paired with two Series C Warrants per share exercisable at $69.46, plus 29.5 million pre-funded warrants. | Not measured | 424B5 |
| IONQ IonQ, Inc. | Oct 14, 2026, 8:39 AM ET | Prospectus supplement (424B5) | IonQ filed a preliminary 424B5 for a ~$2.0 billion offering of 20.5 million shares plus 100 million Series C Warrants and 29.5 million Pre-funded Warrants, with J.P. Morgan as sole underwriter. | Not measured | 424B5 |
| MI NFT Ltd | Oct 13, 2026, 8:55 AM ET | Prospectus supplement (424B5) | NFT Limited (NYSE American: MI) is raising roughly $1.0 million gross ($875,000 net) via a best-efforts offering of 600,000 units at $1.00 plus 400,000 pre-funded units, each pairing a Class A share (or pre-funded warrant) with a five-year... | 5 | 424B5 |
| SBFM Sunshine Biopharma Inc. | Oct 9, 2026, 5:24 PM ET | Priced offering (424B4) | Sunshine Biopharma (Nasdaq: SBFM) priced a best-efforts offering of up to 10,509,082 common units at $0.55 per unit on October 9, 2026, each unit comprising one share and two Series D warrants exercisable at $0.66 for five years, seeking... | 5 | 424B4 |
| MGRX MANGOCEUTICALS, INC. | Oct 9, 2026, 4:00 PM ET | Prospectus supplement (424B5) | Mangoceuticals (MGRX) is raising ~$475K net via a direct offering of 657,000 shares at $0.75 plus warrants, priced at a ~70% premium to the October 7 close of $0.44. | 10 | 424B5 |
| BIAF bioAffinity Technologies, Inc. | Oct 9, 2026, 12:00 PM ET | Prospectus supplement (424B5) | bioAffinity Technologies priced a ~$4.0 million direct offering of 116,545 shares at $6.122 per share, plus pre-funded warrants on up to 536,836 shares and unregistered warrants on 980,072 shares, with WallachBeth acting as exclusive... | 11 | 424B5 |
| SXTC China SXT Pharmaceuticals, Inc. | Oct 9, 2026, 9:30 AM ET | Prospectus supplement (424B5) | China SXT Pharmaceuticals priced a best-efforts offering of up to 8,000,000 units at $1.50 per unit (share or pre-funded warrant plus ordinary warrant) for gross proceeds of up to $12 million, with a 30-day over-allotment option for... | 3 | 424B5 |
| BMGL Basel Medical Group Ltd | Oct 8, 2026, 4:46 PM ET | Priced offering (424B4) | Basel Medical Group (Nasdaq: BMGL) priced a best-efforts public offering of up to 6,000,000 units at US$1.33 per unit, each with one share (or pre-funded warrant) and a common warrant, for maximum gross proceeds of US$7.98 million and... | 2 | 424B4 |
| PCVX Vaxcyte, Inc. | Oct 8, 2026, 4:30 PM ET | Prospectus supplement (424B5) | Vaxcyte priced a $500M follow-on offering of 7,412,500 shares at $64.00 per share, plus pre-funded warrants on 400,000 shares, a roughly 4% discount to the October 6, 2026 close of $66.70, with a 30-day greenshoe on up to 1,171,875... | Not measured | 424B5 |
| MTTN Matternet, Inc. | Oct 7, 2026, 4:06 PM ET | Prospectus supplement (424B5) | Matternet filed Prospectus Supplement No. 4 registering the resale of up to 51,590,925 shares of common stock by selling stockholders, plus up to 3,535,082 warrant shares. | Not measured | 424B5 |
| MI NFT Ltd | Oct 7, 2026, 12:00 PM ET | Prospectus supplement (424B5) | NFT Limited (NYSE American: MI) priced a best-efforts offering of 1,890,000 Units or Pre-Funded Units at $1.35 per Unit, each consisting of one Class A ordinary share (or pre-funded warrant) plus a five-year Common Warrant exercisable at... | 5 | 424B5 |
| NXH NEIGHBORHOOD INTELLIGENCE, INC. | Oct 6, 2026, 8:34 AM ET | Prospectus supplement (424B5) | Neighborhood Intelligence (metadata ticker BBBY, now trading as NXH) filed a 424B5 for a registered direct offering of 11,243,511 shares plus pre-funded warrants on 5,241,997 shares, each paired with warrants on 16,123,189 shares, at a... | 3 | 424B5 |
| PCVX Vaxcyte, Inc. | Oct 5, 2026, 9:24 PM ET | Prospectus supplement (424B5) | Vaxcyte filed a preliminary 424B5 prospectus supplement for an underwritten offering of common stock and pre-funded warrants, concurrent with an offering of convertible senior notes due 2032. | Not measured | 424B5 |
| SKYD Paramount Skydance Corp | Oct 5, 2026, 9:36 AM ET | Prospectus supplement (424B5) | Paramount Skydance filed a 424B5 to register a distribution of up to 471,300,000 transferable warrants, one per Class B share held as of October 5, 2026 (excluding ~622 million shares held by Restricted Holders, the 401(k) Plan and Master... | Not measured | 424B5 |
| DXST Decent Holding Inc. | Oct 5, 2026, 9:30 AM ET | Prospectus supplement (424B5) | Decent Holding Inc. (Nasdaq: DXST) priced a best-efforts offering of up to 177,000 Class A shares at $1.50 per share plus 645,828 pre-funded warrants, for up to ~$1.23 million gross proceeds. | 2 | 424B5 |
| NIVF NewGenIvf Group Ltd | Sep 30, 2026, 8:45 AM ET | Priced offering (424B4) | NewGenIvf Group (NIVF) priced a best-efforts offering of 125,000 Class A shares at $0.07 plus 17,732,143 pre-funded warrants, for $1.25 million gross proceeds. | 3 | 424B4 |
| HYAC Haymaker Acquisition Corp V | Sep 18, 2026, 12:48 PM ET | Priced offering (424B4) | Haymaker Acquisition Corp V, a Cayman Islands blank check company, priced a $250,000,000 IPO of 25,000,000 units at $10.00 per unit, each consisting of one Class A ordinary share and one-third of a redeemable warrant exercisable at $11.50. | Not measured | 424B4 |
| LASE Laser Photonics Corp | Sep 14, 2026, 10:27 AM ET | Priced offering (424B4) | Laser Photonics Corporation (Nasdaq: LASE) filed a final prospectus for a best-efforts public offering of 10,500,000 shares plus Series B-1 and B-2 warrants to purchase up to 21,000,000 additional shares, priced at $0.75 per share and... | 16 | 424B4 |
| LHSW Lianhe Sowell International Group Ltd | Sep 3, 2026, 9:30 AM ET | Priced offering (424B4) | Lianhe Sowell International Group (Nasdaq: LHSW) filed a final 424B4 prospectus for a best-efforts offering of up to 7,638,889 units at $1.44 per unit, each consisting of one Class A ordinary share and three warrants exercisable at $1.66... | 2 | 424B4 |
| APVO Aptevo Therapeutics Inc. | Sep 3, 2026, 9:00 AM ET | Priced offering (424B4) | Aptevo Therapeutics filed a 424B4 prospectus registering the resale by selling stockholders of up to 6,444,858 shares issuable upon exercise of pre-funded warrants (861,708 shares), common warrants (4,308,540 shares) and inducement... | 12 | 424B4 |
| SEV Aptera Motors Corp | Aug 20, 2026, 5:05 PM ET | Priced offering (424B4) | Aptera Motors Corp filed a final prospectus registering the resale of up to 4,320,000 shares of non-voting Class B common stock issuable upon exercise of warrants issued to six selling stockholders in a private placement that closed July... | 7 | 424B4 |
| ABVC ABVC BIOPHARMA, INC. | Aug 17, 2026, 4:19 PM ET | Priced offering (424B4) | ABVC BioPharma filed Prospectus Supplement No. 6 on August 17, 2026, registering 3,400,187 shares of common stock underlying outstanding common stock purchase warrants and incorporating its Form 10-Q for the quarter ended June 30, 2026. | 2 | 424B4 |
| CRIS CURIS INC | Aug 13, 2026, 5:27 PM ET | Priced offering (424B4) | Curis, Inc. priced a $5.6 million gross best-efforts offering of 335,001 shares at $1.50 plus warrants, 3,398,333 pre-funded warrants at $1.49, and 3,733,334 common warrants exercisable at $1.75, with A.G.P. and Laidlaw as placement agents... | 12 | 424B4 |
| SLXN Silexion Therapeutics Corp | Aug 13, 2026, 11:01 AM ET | Priced offering (424B4) | Silexion Therapeutics Corp (SLXN) priced a best-efforts public offering of 2,028,619 ordinary shares with ordinary warrants at $0.65 per unit for total gross proceeds of approximately $2.5 million, plus 1,817,542 pre-funded warrants at... | 19 | 424B4 |
| IPDN Professional Diversity Network, Inc. | Aug 13, 2026, 9:44 AM ET | Priced offering (424B4) | Professional Diversity Network (IPDN) priced a best-efforts public offering of 1,620,000 units at $0.28 and 5,524,000 pre-funded units at $0.2799, each paired with a three-year warrant exercisable at $0.28, for gross proceeds of... | 2 | 424B4 |
| ISPC iSpecimen Inc. | Aug 7, 2026, 9:00 AM ET | Priced offering (424B4) | iSpecimen priced a best-efforts public offering of 996,231 shares at $1.30 per share, alongside pre-funded warrants for up to 2,849,922 additional shares, targeting up to roughly $5.0 million in gross proceeds with E.F. Hutton & Co. as... | 3 | 424B4 |
Warrant terms that matter
- Exercise price
- Warrants far above the market price rarely get exercised; warrants at or below it can turn into shares quickly.
- Pre-funded warrants
- Exercisable for a nominal price, usually $0.0001. Treat them as shares that have not been issued yet.
- Reset and anti-dilution clauses
- Some warrants lower their exercise price, or raise their share count, after a later cheaper offering or a reverse split. These are the terms most often missed.
- Alternative cashless exercise
- Lets holders receive shares without paying cash, sometimes for more shares than a plain cashless formula would give.
- Expiry
- Usually five years from issue for offering warrants.
A company's total warrants outstanding is reported in its latest 10-Q or 10-K, usually in the equity footnote, and changes with every new offering after that. The summary column above shows how many warrant series Signal8 measured in its published dilution summary for the company; "Not measured" means no summary covers it, and "Not yet updated" means the summary was written before this filing; neither means there are no warrants. Full instrument tables with exercise prices are on DilutionScan.